OpenAI收购Orchestra Bio，布局药物研发协调Agent
OpenAI bought Orchestra Bio, whose AI agents track drug programs.
OpenAI与Anthropic同时重金收购生物制药垂直领域团队，标志着AI巨头正从通用模型竞争转向深入产业落地的关键一步，值得密切关注其后续产品化进展。
OpenAI bought Orchestra Bio, whose AI agents track drug programs.
OpenAI 收购了 Orchestra Bio，其 AI 智能体负责追踪药物研发项目。
Until now, Rosalind covered the science: GPT-Rosalind reasons through biology and chemistry, while Rosalind Workbench links models to lab tools and data.
在此之前，Rosalind 专注于科学领域：GPT-Rosalind 能够推理生物学和化学问题，而 Rosalind Workbench 则将模型与实验室工具及数据连接起来。
Orchestra targets a different bottleneck, the coordination work that spreads a drug program across departments, contractors and disconnected software.
Orchestra 旨在解决另一瓶颈，即协调工作——将药物研发项目跨部门、承包商以及孤立软件系统进行整合的协调工作。
Its agents monitor studies and timelines, so when a manufacturing batch fails, they map which trials slip and compare responses for program leaders to choose.
其智能体监控研究进展和时间表，因此当某批制造失败时，它们能映射出哪些试验会延期，并对比各方反应，供项目负责人做出选择。
Anthropic paid roughly $400M in stock for Coefficient Bio in April, so both labs are now buying specialist biology teams.
Anthropic 今年四月以约 4 亿美元的股票收购了 Coefficient Bio，因此这两家实验室如今都在收购专业的生物团队。
Development still averages 10 to 15 years from target to US approval, a clock largely set by trial biology and regulators.
从靶点发现到获得美国批准，平均仍需 10 至 15 年，这一周期主要由试验生物学和监管机构决定。
更进一步：量化金融体系
看懂新闻只是起点——沿量化金融路径，把它变成能交付的工程能力